Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma

Journal of Clinical Oncology

Volumn 23, Issue 4, 2005, Pages 676-684

  O'Connor, Owen A ^a   Wright, John ^a   Moskowitz, Craig ^a   Muzzy, Jamie ^a   MacGregor Cortelli, Barbara ^a   Stubblefield, Michael ^a   Straus, David ^a   Portlock, Carol ^a   Hamlin, Paul ^a   Choi, Elizabeth ^a   Dumetrescu, Otila ^a   Esseltine, Dixie ^a   Trehu, Elizabeth ^a   Adams, Julian ^a   Schenkein, David ^a   Zelenetz, Andrew D ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CORTICOSTEROID; PROTEASOME INHIBITOR; RITUXIMAB; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; PROTEINASE INHIBITOR; PYRAZINE DERIVATIVE;

ADULT; AGED; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER FATIGUE; CANCER REGRESSION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG RESPONSE; DRUG TOLERANCE; FEMALE; FOLLICULAR LYMPHOMA; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPERNATREMIA; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; INFECTION; LEUKOCYTE; LYMPHOCYTOMA; LYMPHOCYTOPENIA; LYMPHOMA; MALE; MANTLE CELL LYMPHOMA; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHIC PAIN; NEUTROPHIL; NEUTROPHIL COUNT; NONHODGKIN LYMPHOMA; PARTIAL THROMBOPLASTIN TIME; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTHROMBIN TIME; SENSORY NEUROPATHY; SIDE EFFECT; THROMBOCYTE COUNT; THROMBOCYTOPENIA; VASCULITIS; MIDDLE AGED;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; FEMALE; HUMANS; LYMPHOMA, MANTLE-CELL; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PROTEASE INHIBITORS; PYRAZINES;

EID: 20044376092     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.02.050     Document Type: Article

References (38)

1. Adams J, Palombella VJ, Elliott PJ: Proteasome inhibition: A new strategy in cancer treatment. Invest New Drugs 18:109-121, 2000
2. Chiarle R, Budel LM, Skolnik J, et al: Increased proteasome degradation of cyclin dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma. Blood 15:619-626, 2000
3. King RW, Deshaies RJ, Peters JM, et al: How proteolysis drives the cell cycle. Science 274:1652-1659, 1996
4. Palombella VJ, Rando OJ, Goldberg AL, et al: The ubiquitin-proteasome pathway is required for processing the NF-kB1 precursor protein and the activation of NF-kB. Cell 78: 773-785, 1994
5. Delic J, Masdehors P, Smura S, et al: The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo- and radioresistant human chronic lymphocytic leukemia lymphocytes to TNF-a-initiated apoptosis. Br J Cancer 77:1103-1107, 1998
6. Frankel A, Man S, Elliott P, et al: Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. Clin Cancer Res 6:3719-3728, 2000
7. Bold RJ, Virudachalam S, McConkey DJ: Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome. J Surg Res 100: 11-17, 2001
8. Hideshima T, Richardson P, Chauhan D, et al: The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 61:3071-3076, 2001
9. Orlowski RZ, Stinchcombe TE, Mitchell BS, et al: Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 20: 4420-4427, 2002
10. Aghajanian C, Soignet S, Dizon DS, et al: A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res 8:2505-2511, 2002
11. Sherr CJ: Cancer cell cycles. Science 274: 1672-1677, 1996
12. Read MA, Neish AS, Luscinskas FW: The proteasome pathway is required for cytokine-induced endothelial leucocyte adhesion molecule expression. Immunity 2:493-506, 1995
13. Zetter BR: Adhesion molecules in tumor metastasis. Semin Cancer Biol 4:219-222, 1993
14. Beg AA, Baltimore D: An essential role for NF-kappa-B in preventing TNF-a induced death. Science 274:782-784, 1996
15. Pham LV, Tamyo AT, Yoshimura LC, et al: Inhibition of constitutive NF-kB activation in mantle cell lymphoma B-cells leads to induction of cell cycle arrest and apoptosis. J Immunol 171: 88-95, 2003
16. Harousseau JL, Shaughnessy J Jr, Richardson P: Multiple myeloma. Hematology (Am Soc Hematol Educ Program) 237-256, 2004
17. An B, Goldfarb RH, Siman R, et al: Novel dipeptidyl proteasome inhibitors overcome bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed but not normal fibroblasts. Cell Death Differ 12: 1062-1075, 1998
18. Davis RE, Brown KD, Siebenlist U, et al: Constitutive nuclear factor kB activity is required for survival of activated B cell like diffuse large B-cell lymphoma cells. J Exper Med 194:1861-1874, 2001
19. Alizadeh AA, Elsen MB, Davis RE, et al: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503-510, 2000
20. Ohshima K, Muta J, Kawasaki C, et al: Bcl10 expression, rearrangement and mutation in MALT lymphoma: Correlation with expression of nuclear factor-kappa-B. Int J Oncol 19:283-289, 2001
21. Vega F, Medeiros LJ: Marginal zone B-cell lymphoma of extranodal mucosa associated lymphoid tissue: Molecular genetics provides new insights into pathogenesis. Adv Anat Pathol 8:313-326, 2001
22. Adams J, Behnke M, Chen S, et al: Potent and selective inhibitors of the proteasome: Dipeptidyl boronic acids. Bioorg Med Chem Lett 8:333-338, 1998
23. Cheson BD, Horning SJ, Coiffier B. et al: Report of an International Workshop to standardize response criteria for non-Hodgkin's lymphoma. J Clin Oncol 17:1244-1253, 1999
24. Cheson BD, Bennett JM, Grever M, et al: National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment. Blood 87:4990-4997, 1996
25. Richardson PG, Barlogie B, Berenson J, et al: A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348:2609-2617, 2003
26. Marshansky V, Wang X, Bertrand R, et al: Proteosomes modulate balance among proapoptotic and antiapoptotic bcl-2 family members and compromise functioning of the electron transport chain in leukemic cells. J Immunol 166: 3130-3142, 2001
27. Ling YH, Liebes L, Ng B, et al: PS-341, a novel proteasome inhibitor, induces bcl-2 phosphorylation and cleavage in association with G2-M arrest and apoptosis. Mol Cancer Ther 1:841-849, 2002
28. Ling YH, Liebes L, Jiang JD, et al: Mechanisms of proteasome inhibitor PS-341-induced G2-M phase arrest and apoptosis in human non-small cell lung cancer cell lines. Clin Cancer Res 9:1145-1154, 2003
29. Teodorovic I, Pittaluga S, Kluinnelemans JD, et al: Efficacy of four different regimens in 64 mantle cell lymphoma cases: Clinicopathologic comparison with 498 other non-Hodgkin's lymphoma subtypes. J Clin Oncol 13:2819-2826, 1995
30. Norton AJ, Mattews J, Papa V, et al: Mantle cell lymphoma: Natural history defined in a serially biopsied population over a 20 year period. Ann Oncol 6:249-256, 1995
31. Argatoff LH, Connors JM, Klasa RJ, et al: Mantle cell lymphoma: A clinicopathologic study of 80 cases. Blood 89:2067-2078, 1997
32. Meusers P, Engelhard M, Bartels H, et al: Multicentre randomized therapeutic trial for advanced centrocytic lymphoma: Anthracycline does not improve the prognosis. Hematol Oncol 7:365-380, 1989
33. Zucca E, Roggero E, Pinotti G, et al: Patterns of survival in mantle cell lymphoma. Ann Oncol 6:257-282, 1995
34. Fischer RI, Dahlberg S, Nathwani BN, et al: A clinical analysis of two indolent entities: Mantle cell lymphoma and marginal zone lymphoma (including mucosa associated lymphoid tissue and monocytoid B-cell subcategories)-A Southwest Oncology Group Study. Blood 85:1075-1082, 1995
35. Coiffier B: Which treatment for mantle cell lymphoma patients in 1998? J Clin Oncol 16:3-5, 1998
36. Goy A, Hart S, Pro B, et al:. Report of a phase II study of proteasome inhibitor bortezomib (Velcade) in patients with relapsed or refractory indolent or aggressive lymphoma. Blood 102, 2003 (abstr 627)
37. Assouline S, Belch A, Sehn L, et al: A phase II study of bortezomib in patients with mantle cell lymphoma. Blood 102, 2003 (abstr 3358)
38. O'Connor OA, Srinicasan S, Hernandez F, et al: Oblimersen enhances the antitumor activity of bortezomib in multiple myeloma and non-Hodgkin's lymphoma in preclinical models. Proc Am Soc Hematol 2003 (abstr 628)